medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 3

<< Back Next >>

Rev Invest Clin 2014; 66 (3)

ALECT2 amyloidosis: a new type of systemic amyloid highly prevalent in the Hispanic population

Jiménez-Zepeda VH, Leung N

Language: English
References: 21
Page: 269-273
PDF size: 131.04 Kb.


ABSTRACT

Amyloidosis results from extracellular deposition of fibril-forming proteins and currently ~30 different proteins have been found to be amyloidogenic. Recently, a novel type of amyloidosis with a high incidence on Hispanic population has been described to be derived from leukocyte chemotactic factor 2 (ALECT2). The objective of the present article is to raise awareness on the presence of this entity for the medical community in México. ALECT2 is a clinical entity characterized by deposition of the LECT2 protein mainly on liver and kidney. Renal ALECT2 affects elderly Hispanics who present with chronic renal insufficiency and bland urine sediment, not always associated to proteinuria. No treatment guidelines are reported for this disease but support measures including organ transplantation when required are recommended. Further genetic and clinical characterization of this entity is needed to help understanding the mechanisms by which this protein becomes amyloidogenic and how to prevent organ damage related to its deposition.


REFERENCES

  1. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208-19.

  2. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-9.

  3. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000; 130: 88-98.

  4. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81: 693-703.

  5. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int 2008; 74: 218-22.

  6. Mereuta OM, Theis JD, Vrana JA, et al. Mass spectrometry-based proteomics reveals that leukocyte cell-derived chemotaxin 2 associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood 2014; 123: 1479-82.

  7. Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki K. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 1996; 52: 9-13.

  8. Hiraki Y, Inoue H, Kondo J, et al. A novel growth-promoting factor derived from fetal bovine cartilage, chondromodulin II. Purification and amino acid sequence. J Biol Chem 1996; 271: 22657-62.

  9. Yamagoe S, Kameoka Y, Hashimoto K, Mizuno S, Suzuki K. Molecular cloning, structural characterization, and chromosomal mapping of the human LECT2 gene. Genomics 1998; 48: 324-9.

  10. Larsen CP, Kossmann RJ, Beggs ML, Solomon A, Walker PD. Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int 2014 [Epub ahead of print].

  11. Theis JDDS, Vrana, JA, Mereuta O, Grogg K, Gertz M, Zeldendrust S, Dispenzieri K and Dogan A. Proteome of amyloidosis: Mayo Clinic Experience in 4139 cases. Blood 2013; 2013: 1900.

  12. Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 2014.

  13. Dogan ATJ, Vrana JA, Jimenez-Zepeda V, Fonseca R. Clinical and pathological phenotype of leukocyte cell-derived chemotaxin- 2 (LECT2) amyloidosis (ALECT2). Amyloid 2010; 17: 69-70.

  14. Murphy CL, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010; 56: 1100-07.

  15. Jimenez-Zepeda VH. AL amyloidosis: an epidemiological and clinical challenge. Rev Invest Clin 2013; 65: 357-8.

  16. Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2013; 120: 3206-13.

  17. Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant 2012; 27: 1097-101.

  18. Sethi S, Theis JD, Vrana JA, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, Jiménez-Zepeda VH, et al. ALECT2, amyloidosis, renal dysfunction. Rev Invest Clin 2014; 66 (4): 269-273 273 fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 915-21.

  19. Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226-34.

  20. Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180-7.

  21. Murphy C, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis. Amyloid 2010; 18(Suppl. 1): 223-5.




2020     |     www.medigraphic.com